SAFE & EFFECTIVE

 

As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months2

 

TAVR SHOWED LOWER MORTALITY, FEWER DISABLING STROKES, AND FEWER HEART FAILURE REHOSPITALIZATIONS COMPARED TO SAVR2

Chart comparing mortality data at one year for TAVR and SAVR patients.

 

HEMODYNAMICS
FOR THE
LONG RUN

Evolut™ TAVR is the only TAVR device to demonstrate hemodynamic superiority in a low-risk clinical trial vs. SAVR1

Graphic depicting Evolut offers superior EOAs and gradients at 1 year compared to SAVR.
Smiling couple plays on the beach

FASTER
RETURN
TO AN
ACTIVE
LIFE

EVOLUT TAVR SUPERIOR TO SAVR
in self-reported KCCQ measures at 30 days1

58% SHORTER HOSPITAL STAY
with TAVR procedures vs. SAVR procedures2

LOWER RATES OF REHOSPITALIZATION
with Evolut TAVR vs. SAVR2

1

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

2

Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.